Company Description
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States.
Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients.
The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout.
Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
| Country | United States |
| Founded | 2018 |
| IPO Date | Apr 29, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 41 |
| CEO | Yu-Hsin Lin |
Contact Details
Address: 12750 High Bluff Drive, Suite 475 San Diego, California 92130 United States | |
| Phone | 858 246 6240 |
| Website | belitebio.com |
Stock Details
| Ticker Symbol | BLTE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $6.00 |
| CIK Code | 1889109 |
| CUSIP Number | 07782B104 |
| ISIN Number | US07782B1044 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Yu-Hsin Lin M.B.A., Ph.D. | Chairman of the Board of Directors and Chief Executive Officer |
| Hao-Yuan Chuang C.F.A., F.R.M., M.B.A. | Chief Financial Officer and Director |
| Dr. Nathan L. Mata Ph.D. | Chief Scientific Officer |
| Dr. Hendrik P.N. Scholl M.A., M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 21, 2026 | 6-K | Report of foreign issuer |
| Apr 15, 2026 | 144 | Filing |
| Apr 9, 2026 | 144 | Filing |
| Apr 9, 2026 | 144 | Filing |
| Apr 9, 2026 | 144 | Filing |
| Mar 31, 2026 | 6-K | Report of foreign issuer |
| Mar 31, 2026 | 20-F | Annual and transition report of foreign private issuers |
| Mar 2, 2026 | 6-K | Report of foreign issuer |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Jan 30, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |